Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832129 | 0.69 | PNMT (0.39) | ALOX15HSD17B10MEN1GAAKMT2A | |
| SCHEMBL4792502 | 0.67 | ALOX15 (0.30) | ALOX15HSD17B10 | |
| SCHEMBL29408147 | 0.66 | GAA (0.54) | ALOX15HSD17B10MEN1GAAKMT2A | |
| SCHEMBL123812 | 0.66 | GAA (0.54) | ALOX15HSD17B10MEN1GAAKMT2A | |
| SCHEMBL30549 | 0.66 | — | — | |
| SCHEMBL29144954 | 0.66 | GAA (0.54) | ALOX15HSD17B10MEN1GAAKMT2A | |
| SCHEMBL20307 | 0.66 | — | — | |
| SCHEMBL3876165 | 0.66 | GAA (0.36) | ALOX15MEN1GAAKMT2AMAPT | |
| SCHEMBL1926927 | 0.66 | — | — | |
| SCHEMBL313033 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2921 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265111-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | claimed |
| US-RE49361-E1 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-01-10 | — | — | US | claimed |
| US-20220009948-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | claimed |
| US-20210198289-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-01 | — | — | US | claimed |
| CN-107108588-B | Fused bicyclic (hetero) aromatic compounds useful for the treatment of cancer | 杰资制药爱尔兰有限公司 | 2021-06-01 | — | — | CN | claimed |
| EP-3386511-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2021-05-12 | — | — | EP | claimed |
| US-10874672-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | claimed |
| US-20200392164-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-17 | — | — | US | claimed |
| US-20200181176-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-11 | — | — | US | claimed |
| US-10450318-B2 | CXCR4 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-22 | — | — | US | claimed |
| US-5739130-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS, MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-14 | — | — | US | claimed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | claimed |
| US-5583135-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS OR MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-10 | — | — | US | claimed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| EP-0728003-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | claimed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | claimed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| US-5225589-A | Organic compositions and their manufacture | EASTMAN KODAK COMPANY (US) | 1993-07-06 | — | — | US | claimed |